Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein and glutamate-preferring carboxypeptidase with roles in folic acid utilization and metabolism that is encoded by FOLH1 in humans.1,2 It is composed of a short intracellular sequence, a transmembrane domain, and a large extracellular region, which contains enzymatic domains.1,3 PSMA is expressed in prostate epithelial cells and in the proximal small intestine, where it promotes folate uptake by cleaving glutamate from folypoly-γ-glutamate, and in the central nervous system, where it regulates neurotransmitter activity by cleaving glutamate from N-acetyl-aspartyl-glutamate (NAAG).2,4 It is also highly overexpressed in prostate carcinomas and in the neovasculature of various renal, colon, and breast carcinomas to support the need for folate in these rapidly dividing cells.2,4 Expression of FOLH1 increases under androgen deprivation conditions in vitro and in vivo and positively correlates with cancer aggressiveness in patients with prostate cancer.1 PSMA PET imaging is commonly used in the diagnosis and staging of prostate cancer, as well as to assess therapeutic response.3 Cayman's PSMA Extracellular Domain (human, recombinant) - Biotinylated protein consists of 732 amino acids and has a calculated molecular weight of 82.72 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 99.7 kDa due to glycosylation.WARNING This product is not for human or veterinary use.